158 related articles for article (PubMed ID: 36002754)
21. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J
Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657
[TBL] [Abstract][Full Text] [Related]
23. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
24. Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients.
Zhang D; Wang Y; Zhao F; Yang Q
Comput Biol Med; 2023 Jun; 159():106866. PubMed ID: 37068318
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Nomogram for Overall Survival in Small Cell Lung Cancer Patients Treated with Chemotherapy: A SEER-Based Retrospective Cohort Study.
Liang M; Chen M; Singh S; Singh S
Adv Ther; 2022 Jan; 39(1):346-359. PubMed ID: 34729705
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel prognostic signature for HCC and analysis of costimulatory molecule-related lncRNA AC099850.3.
Wang Q; Fang Q; Huang Y; Zhou J; Liu M
Sci Rep; 2022 Jun; 12(1):9954. PubMed ID: 35705628
[TBL] [Abstract][Full Text] [Related]
28. Effect of histological subtype and treatment modalities on T1-2 N0-1 small cell lung cancer: A population-based study.
Moon SW; Seo JH; Jeon HW; Moon MH
Thorac Cancer; 2019 May; 10(5):1229-1240. PubMed ID: 30993901
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.
He L; Huang Y; Chen X; Huang X; Wang H; Zhang Y; Liang C; Li Z; Yan L; Liu Z
Front Immunol; 2022; 13():835630. PubMed ID: 35401554
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
32. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
33. A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection.
Atay S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958393
[TBL] [Abstract][Full Text] [Related]
34. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
35. Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.
Wang Y; Han X; Wang X; Sheng W; Chen Z; Shu W; Han J; Zhao S; Dai Y; Wang K; Shi W; Yang Z
Jpn J Clin Oncol; 2019 Dec; 49(12):1143-1150. PubMed ID: 31612912
[TBL] [Abstract][Full Text] [Related]
36. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer.
Pandey M; Mukhopadhyay A; Sharawat SK; Kumar S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188552. PubMed ID: 33892053
[TBL] [Abstract][Full Text] [Related]
37. Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities.
Yang L; Zhang Z; Dong J; Zhang Y; Yang Z; Guo Y; Sun X; Li J; Xing P; Ying J; Zhou M
Pharmacol Res; 2023 Aug; 194():106844. PubMed ID: 37392900
[TBL] [Abstract][Full Text] [Related]
38. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH; Wang HL; Xing TJ; Wang XQ
Front Immunol; 2022; 13():851622. PubMed ID: 35924232
[TBL] [Abstract][Full Text] [Related]
39. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
Bi N; Cao J; Song Y; Shen J; Liu W; Fan J; He J; Shi Y; Zhang X; Lu N; Zhan Q; Wang L
PLoS One; 2014; 9(3):e91388. PubMed ID: 24637927
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy.
Jin S; Cao S; Xu S; Wang C; Meng Q; Yu Y
Clin Respir J; 2018 Sep; 12(9):2433-2440. PubMed ID: 30074685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
